Dr. Brahmayya Sastry Memorial Oration organised in Vizag
Dr. Sastry was an Emeritus Professor, ICMR Scientist and SMR Scientist and worked for 17 years in the Department of Physiology after his retirement as Principal of Andhra Medical College (AMC). A student of Prof Mc Intosh in Mc Gill University, Canada, Dr. Sastry had pursued his research under his tutelage. From Dr. T. Desi Raju, recipient of Santhi Swaroop Bhatnagar Award, to Dr. T. Ravi Raju, who heralded a new dawn in nephrology through his research on Chronic Kidney Diseases (CKD) of unknown origin in Srikakulam district, Dr. Sastry had mentored many luminaries in their respective fields.
Dr. D. Nageshwar Reddy, who has received all the three Padma Awards for his contribution to the field of gastroenterology, and Dr. Prabhir Roy Chaudhury, a prominent Nephrologist, and president of American Society of Nephrology, gave the orations.
Dr. Nageshwar Reddy who spoke on the qualities of a 'good doctor' called upon medical students to learn to empathise with the patient in addition to acquiring the required skills in their area of specialisation. He expressed regret that empathy has become a rare quality with monetary gains becoming the sole criteria.
Dr. Prabhir Roy Chaudhury who spoke on 'chronic kidney diseases of unknown origin' said that no significant research could be done in the last three decades to save kidney patients from the prospect of undergoing frequent dialysis. The inequities in availability of treatment due to high cost was another area of concern. However, some research has been going on, of late, and he hoped that a breakthrough would be achieved soon.
Earlier, Dr. T. Ravi Raju, Chairperson, AMC Centenary Alumni Building Committee dedicated the building to the alma mater.
Dr KVSM Sandhya Devi, Principal, AMC, Dr. SKE Appa Rao, president, AMCOSA, Dr. Manikam Mutyala, president, AMC Association of North America (AMCANA) and Dr. I. Vani, Superintendent, King George Hospital (KGH), and Dr. PV Sudhakar, former Principal, AMC, were among those who participated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Print
13 hours ago
- The Print
SB43154 drug used in cancer research shows promise against COVID-19 in preclinical studies: Scientists
This discovery was a collaborative effort between the National Centre for Veterinary Type Culture in Hisar and National Institute of Virology (NIV) under the ICMR in Pune, said NIV Director Dr Naveen Kumar. Remarkably, even after more than 50 consecutive generations exposed to the drug, the virus was unable to develop resistance. Scientists from the Indian Council of Medical Research (ICMR) and Indian Council of Agricultural Research (ICAR) have jointly found that the drug — SB431542, an ALK5 inhibitor — is highly effective against the coronavirus. New Delhi, Jul 28 (PTI) After a long battle and research, Indian scientists have found out that a drug used in cancer studies has the potential to provide substantial protection against the coronavirus infection in preclinical studies. The study was first released as a preprint on bioRxiv and has since been accepted for publication in the Journal of Virology. If future human trials confirm its effectiveness, the drug could become a groundbreaking tool in the fight against COVID-19. Since December 2019, when the coronavirus emerged from China's Wuhan, it has spread to nearly every country in the world. Since 2020, more than 30 anti-Covid vaccines have received the World Health Organization's (WHO) approval for global use. 'However, health experts believe vaccines alone are not enough. The virus continues to mutate, and many existing treatments like Remdesivir and monoclonal antibodies will quickly lose effectiveness,' Kumar said. In this context, Indian scientists have been screening small molecule inhibitors that mainly target cellular kinases and phosphatases. One such compound, SB431542 — originally developed to block TGF-β (Transforming Growth Factor-beta) signalling and commonly used in preclinical cancer, inflammation and fibrosis research — has now been found by Indian researchers to also inhibit the coronavirus effectively. Kumar explained that SB431542 fights the virus in three fronts. It first blocks the virus from entering human cells by targeting the TGF-β/Smad pathway. Secondly, it disrupts the ability of the virus to assemble inside cells by interfering with ORF3a-related lysosomal dysfunction. Finally, it prevents the virus from killing the infected cell (a process called apoptosis), which helps stop the virus from escaping and spreading to other cells. This three-pronged approach has not been observed in any existing antiviral drug. Interestingly, the drug acted through both direct and indirect mechanisms — it directly targets the viral ORF3a protein and indirectly hinders the virus by blocking the host cell's TGF-β signaling pathway. SB431542 was also tested against the chicken coronavirus (Infectious Bronchitis Virus or IBV) in specific pathogen-free chicken embryos. Embryos treated with the drug developed normally and showed no mortality, while those in the untreated control group failed to develop properly and did not survive. Kumar emphasised that even after exposing the virus to the drug over 50 successive generations (passage), it failed to develop resistance. This suggests that the chances of the virus evolving a drug-resistant variant against this compound are extremely low. This is a major advancement over existing antivirals like Remdesivir, against which the virus builds resistance quickly. PTI PLB RC This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Time of India
14 hours ago
- Time of India
"Running Out of Cures": Experts warn of India's silent AMR catastrophe
New Delhi: Antimicrobial resistance (AMR) is no longer a looming global health threat—it is already here, silently claiming thousands of lives across India every week. Infections that were once treatable are now proving deadly, and doctors are increasingly witnessing the failure of even last-resort antibiotics. In a recent ETHealthworld webinar titled 'Running Out of Cures: A Deep Dive into India's Antimicrobial Resistance Crisis,' leading clinicians, researchers, and public health experts dissected the alarming rise of AMR and what India must do—urgently—to contain the fallout. 'When Nothing Works': A Clinician's Dilemma Dr. Tanu Singhal, Infectious Disease Specialist at Mumbai's Kokilaben Dhirubhai Ambani Hospital, recalled devastating cases where no antibiotic proved effective. One such case involved a liver transplant patient battling multiple infections, including a highly drug-resistant Enterococcus faecium. 'The infection was resistant to vancomycin, daptomycin, and linezolid. The only option was tigecycline—unsuitable for bacteremia. We eventually lost her. She left against medical advice, unable to afford prolonged care, and died en route to her home,' she said. Even when effective drugs exist, the cost can be prohibitive. 'We had to import cefiderocol rupees four lakh per day—for an patient with Acinetobacter pneumonia. Though we cured the infection, the patient eventually died of a heart attack due to prolonged hospitalization,' she added. In neonatal care, the scenario is no better. 'Gone are the days when ampicillin and gentamicin were enough. We now see newborns with carbapenem-resistant infections requiring colistin and even imported drugs like cefiderocol,' Dr. Singhal warned, citing India-specific studies showing alarmingly high resistance rates in neonatal sepsis. Hospitals Prepared, But Surveillance Still Fragile While larger hospitals are equipped to manage outbreaks, challenges persist, particularly in smaller and rural facilities. 'Accredited hospitals have adequate manpower and isolation infrastructure for MDR cases,' said Dr. Anita Arora, Director of Medical Operations and IPC Head at Fortis Healthcare. 'But gaps exist in standardization and surveillance, especially across the country's vast non-accredited and tier-2, tier-3 healthcare facilities.' Dr. Raman Gangakhedkar, former ICMR scientist and Distinguished Professor at Symbiosis International University, pointed out the lack of robust, generalizable AMR surveillance data as a major impediment to public health action. 'ICMR's surveillance network includes 20-odd urban tertiary hospitals. That doesn't reflect the national AMR burden. Surveillance must extend to secondary and primary care levels—and even into communities—if we want real change,' he emphasised. India's National Action Plan on AMR, nearing a decade since launch, remains limited in its implementation. 'We have a policy, but not a vertical program like for TB or HIV. That's why AMR doesn't get priority in funding or policy enforcement,' Dr. Gangakhedkar noted. Despite sepsis from multi-drug resistant organisms becoming one of India's top infectious killers, there is no emergency response system. 'We lack a coordinated, multi-stakeholder approach. Without demand from the public or advocacy from clinicians, every death remains anecdotal,' he warned. Dr. Taslimarif Saiyed, Director and CEO of C-CAMP, highlighted the emerging biotech response to AMR through the India AMR Innovation Hub (IAIH). 'Over 80 new diagnostic and therapeutic innovations are in the pipeline, including point-of-care detection tools, small-molecule therapies, peptides, and even mAbs,' he said. Within five years, IAIH aims to bring 15–20 AMR solutions to market. 'Our focus is on affordability, accessibility, and adaptability to Indian healthcare settings. We are also partnering with state governments to test and deploy these solutions,' Dr. Saiyed said. What Fuels the AMR Crisis? Rampant over-the-counter (OTC) use and physician-driven overprescription are key drivers. 'We frequently see patients self-medicating with azithromycin for fever,' said Dr. Singhal. 'There's an urgent need for public campaigns discouraging this behavior and educating people that antibiotics are not for viral infections.' Physician behavior must also change. 'Nearly 70% of outpatient visits are viral, yet antibiotics are often prescribed. Pharmacies dispensing antibiotics without prescriptions must be stopped. The government should crack down on irrational fixed-dose combinations and improve antibiotic quality,' she added. India's AMR crisis is tightly linked to its infectious disease burden. 'If we reduce infections, we automatically reduce antibiotic use,' Dr. Singhal argued. 'Better water, sanitation, hygiene, and vaccination—like typhoid vaccines—are critical long-term AMR containment tools.' A Call for National Coordination and Accountability All experts agreed that AMR cannot be tackled in silos. 'This is not just a medical or regulatory issue. It's a community issue, a veterinary issue, a poultry issue, a pharma issue. Everyone must be accountable,' Dr. Gangakhedkar stressed. Dr. Arora echoed that sentiment: 'No irrational antibiotic combinations should be manufactured or prescribed—anywhere. Regulatory agencies must crack down at the state level, and hospitals must not allow irrational drugs inside their doors.' India's AMR crisis is no longer silent—it is deafening for those willing to listen. But without systemic surveillance, public advocacy, rational prescription practices, and coordinated innovation, the country risks running out of curative options. As Dr. Gangakhedkar summed it up: 'Every patient asking, 'Do I really need this antibiotic?' is a step forward. Every death from untreatable infection must not be forgotten—it must become a rallying cry for urgent action.'
The Hindu
a day ago
- The Hindu
Brain tumours: when a headache, memory lapse, or seizure deserves a second look
Every year, over 40,000 individuals in India are diagnosed with brain tumours, according to data from the Indian Council of Medical Research (ICMR). Yet, in many cases, the diagnosis comes too late. The early warning signs—often subtle, fleeting, or mistaken for everyday stress—are overlooked until symptoms become severe. Following the observance of World Brain Day on July 22 , it is vital to recognise that timely diagnosis and multidisciplinary care can make a significant difference in not only survival, but also in long-term recovery and quality of life for patients and their families. When the body whispers Brain tumours are complex. They vary in type, location, and behaviour—and so do their symptoms. In clinical practice, I often see patients who, in hindsight, experienced signs long before their diagnosis. These early symptoms are frequently dismissed as benign issues: a tension headache, forgetfulness, vision strain, or clumsiness. Common symptoms of brain tumours include: Persistent or worsening headaches Memory lapses or personality changes Difficulty in speaking or finding words Blurred or double vision New-onset seizures Trouble with balance or coordination It is important to understand that many of these symptoms—particularly headaches, giddiness, or occasional forgetfulness—are very common and more often than not due to benign conditions like migraines, tension headaches, or positional vertigo. Not every headache warrants a brain scan. However, when these symptoms are unusual in pattern, progressively worsening, or accompanied by other neurological signs, a medical evaluation is essential. The key challenge is that these symptoms can appear mild or sporadic, leading to delays in seeking medical attention. But when the brain is affected—even subtly—it often tries to signal distress. We need to listen more closely. Children are not immune One of the most overlooked realities is that brain tumours affect children too. Among paediatric populations, tumours in the cerebellum—such as medulloblastoma—are relatively common. The signs, however, may not always be easy to spot. In children, red flags include: Headaches, especially in the morning Repeated vomiting without a clear cause Unsteady gait or difficulty walking Clumsiness or frequent falls Unlike adults, children may not articulate their discomfort clearly. A parent's intuition, in such cases, becomes crucial. Prompt neurological evaluation can lead to early diagnosis and treatment, which significantly improves outcomes. With timely surgery, radiation, chemotherapy, and structured rehabilitation, many children not only survive but go on to live full, healthy adult lives. The ripple effects of a brain tumour The impact of a brain tumour extends far beyond the individual. It disrupts family dynamics, imposes financial burdens, and creates emotional strain for caregivers. It can affect workplace productivity and community engagement. That is why recovery must be viewed not just through a medical lens but a social one. When treated early, many patients return to school, work, and community life. The difference lies in how quickly the tumour is recognised and how comprehensively it is managed. The power of modern tools and teamwork Neuro-oncology teams use a suite of advanced tools designed to enhance precision and safety: neuronavigation systems function like GPS during surgery, guiding the surgeon with remarkable accuracy. High-resolution operating microscopes allow us to see deep brain structures clearly. Awake craniotomy enables patients to stay awake during surgery to protect speech and movement centres. Intraoperative neurophysiological monitoring helps preserve critical brain functions during complex procedures. Comprehensive post-operative rehabilitation ensures that recovery continues well beyond the operating room. These innovations help us safely access delicate regions of the brain while preserving the patient's independence and cognitive function. A realistic, hopeful outlook While early detection improves prognosis, it is important to acknowledge that not all brain tumours behave predictably. Some aggressive tumours may resist treatment even when diagnosed early. Others may lie dormant and symptom-free for extended periods. That said, the opportunity for meaningful intervention exists at nearly every stage. Whether through surgical removal, chemotherapy, radiation, or supportive therapies, modern neuro-oncology offers real hope—particularly when treatment is tailored to the individual. Brain tumours don't always present dramatically. They may arrive disguised as a persistent headache, an uncharacteristic lapse in memory, or a subtle speech difficulty. In children, they may be hidden behind a morning vomit or a minor fall. These are not signs to ignore. This World Brain Day, let us renew our commitment to awareness and early action. By paying attention to the whispers, we can catch the signs sooner, act faster, and improve the lives of those affected. Because sometimes, listening to the smallest signals leads to the biggest differences. (Dr. Komal Prasad C. is a senior consultant – neurosurgery, Narayana Health City, Bengaluru. drkomalprasad@
